X4 Pharmaceuticals (XFOR)

• Market cap: $352M
• 1 day: -3.12%
• 5 days: -5.57%
• 1 month: -17.11%
• 3 months: -19.96%
• 6 months: -4.11%
• Year to date: -4.11%
• 1 year: 4.78%
• 5 years: -98.68%
• 10 years: -99.85%
• Sector: Healthcare
• Industry: Biotechnology

About: X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 45